2-Aminopyrimidine compounds, their preparation methods and applications
By mimicking the ATP structure with 2-aminopyrimidine compounds to bind to the HPK1 protein, the problems of nuclear skeleton convergence and poor selectivity of HPK1 inhibitors were solved, achieving nanomolar-level HPK1 kinase inhibition and significant anti-tumor proliferation effects, overcoming the limitations of cell membrane permeability.
Patent Information
- Application Number
- CN202611597820.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-15
- Publication Date
- 2026-11-10
AI Technical Summary
Existing HPK1 inhibitors suffer from problems such as nuclear skeleton convergence, poor selectivity, low efficiency in converting molecular activity to cellular activity, and unclear systemic structure-activity relationships, resulting in low research and development efficiency and high risk.
Using 2-aminopyrimidine compounds as the parent nucleus, combined with benzenesulfonamide and diaryl ether characteristic side chains, it mimics the ATP structure and binds to HPK1 protein, forming stable hydrogen bonds and electrostatic interactions, enhancing binding affinity, and overcoming cell membrane permeability limitations.
It achieves nanomolar-level HPK1 kinase inhibitory activity and significant anti-tumor proliferation effect, breaking through the limitations of existing drugs and providing highly efficient cell membrane permeability and target binding ability.
Smart Images

Figure CN123062402A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of medicinal chemistry. More specifically, this invention relates to a class of novel 2-aminopyrimidine compounds and their pharmaceutically acceptable salts, as well as methods for preparing them as inhibitors of hematopoietic progenitor cell kinase 1 (HPK1) and their use in the preparation of antitumor drugs. Background Technology
[0002] Hematopoietic progenitor kinase 1 (HPK1), also known as mitogen-activated protein kinase 1 (MAP4K1), is a key negative regulator in the T cell receptor (TCR) signaling pathway. HPK1 can inhibit T cell activation and proliferation by phosphorylating the adaptor protein SLP-76, ultimately mediating tumor immune escape. Based on this mechanism, inhibiting HPK1 can relieve its negative regulatory effect on the T cell signaling pathway and enhance the body's anti-tumor immune response. HPK1 has now become a promising new drug target in the field of tumor immunotherapy.
[0003] Currently, the development of HPK1 small molecule inhibitors faces four major technological bottlenecks:
[0004] 1. Converging core structures and high patent barriers: The core skeletons of existing HPK1 inhibitors (including compounds in clinical development such as AZ3246) are highly homogeneous, novel chemical skeletons are scarce, the range of chemical spaces available for innovative derivation is narrow, and the risk of intellectual property infringement is prominent in the process of new drug development.
[0005] 2. Poor selectivity of MAP4K family kinase subtypes: HPK1 belongs to the MAP4K kinase family, and the proteins of each subtype of this family are involved in regulating a variety of differential physiological functions in the body; existing small molecule inhibitors generally lack excellent selectivity for MAP4K2, MAP4K3, MAP4K4, MAP4K5 and other subtypes of the same family, which easily leads to off-target effects and poses a potential risk of inducing unexpected toxic side effects.
[0006] 3. Low conversion efficiency between molecular kinase inhibitory activity and cellular pharmacological activity: Most existing inhibitors fail to effectively match HPK1 kinase inhibitory activity at the molecular level with antiproliferative activity at the cellular level; although many compounds can achieve nanomolar-level HPK1 kinase inhibition IC50, this is a significant challenge. 50 However, due to defects in physicochemical properties such as cell membrane permeability, cell activity only reaches the micromolar level, or even has no cell efficacy at all, which greatly limits its subsequent pharmaceutical development value.
[0007] 4. Lack of systematic structure-activity relationship data: For the series of HPK1 inhibitor compounds with novel scaffold structures, the regulatory mechanisms of different substitution sites on molecular inhibitory activity, subtype selectivity and pharmacokinetic parameters are not yet clear. This results in a lack of systematic theoretical guidance for the optimization of lead compound structures, leading to a long overall R&D cycle and low R&D efficiency.
[0008] In summary, the key technical challenge that needs to be addressed in this field is to develop a series of HPK1 inhibitor compounds that possess novel chemical skeletons, independent intellectual property rights, excellent selectivity for MAP4K family subtypes, and exhibit potent anti-tumor activity at the cellular level. Summary of the Invention
[0009] This invention provides 2-aminopyrimidine compounds, their preparation methods, and applications, overcoming the bottleneck of "molecular-cellular" activity disconnect commonly encountered in inhibitor development and solving the technical problem of existing inhibitors being "strong in vitro but weak in cellular." The 2-aminopyrimidine compounds of this invention use 2-aminopyrimidine as the core, with the 2-aminopyrimidine ring mimicking the adenine moiety of the endogenous ligand ATP, acting as a "hinge region binding fragment." This fragment forms a stable bidentate hydrogen bond interaction network with key amino acid residues (Glu 92 and Cys 94) in the hinge region of the HPK1 protein, forming the structural basis for the HPK1 inhibitory activity of the entire series of compounds. Characterized by benzenesulfonamide and diaryl ether side chains, the sulfonyl group mimics the phosphate group of ATP, forming a strong electrostatic interaction with basic amino acid residues deep in the target pocket, significantly enhancing the binding affinity of the compound to HPK1. The diaryl ether side chain faces the solvent-accessible region of HPK1. The series of 2-aminopyrimidine compounds of this invention achieve potent nanomolar inhibition of HPK1 kinase and overcome the limitations of cell membrane permeability, exhibiting significantly superior antitumor proliferative activity compared to existing drugs at the cellular level. In particular, compound PXW-5 achieves a significant half-maximal inhibitory concentration (IC50) for HPK1 kinase. 50 The kinase inhibitory activity was 10.35 nM, which was at the same level as the positive control drug AZ3246 (IC50 = 8.33 nM). At a concentration of 20 μM, the proliferation inhibition rate of A549 human non-small cell lung cancer cells was as high as 71.94%, and its cell activity and "molecular-cell" activity conversion efficiency were significantly better than those of the positive control drug AZ3246.
[0010] To achieve these objectives and other advantages according to the invention, a 2-aminopyrimidine compound having the structure shown in general formula (I) or a pharmaceutically acceptable salt thereof is provided.
[0011] (I);
[0012] Wherein, R1 is selected solely from an oxygen-bridged biaromatic ring structural unit, a carbonyl-bridged biaromatic ring structural unit, or a benzo[a]heterocyclic ring; R2 is selected solely from a halogen; R3 is a 4-position substituent of the benzene ring of benzenesulfonamide, and R3 is selected solely from C1-C6 alkyl, C1-C6 alkoxy, ... Wherein, R5 is a C1 to C3 alkyl group, or In this case, R6 is a C1 to C3 alkyl group.
[0013] Preferably, the bridged benzene ring is R4 is selected independently from hydrogen, methyl, or methoxy.
[0014] Preferably, the benzo[a]heterocyclic ring is... .
[0015] Preferably, R2 is Cl.
[0016] Preferably, R3 is methyl, methoxy, tert-butyl, or... , or .
[0017] The present invention also provides a method for preparing 2-aminopyrimidine compounds, comprising the following steps:
[0018] S1. Using 2,4,5-trichloropyrimidine as a starting material, it reacts with R3-substituted benzenesulfonamide under the presence of a base and under nitrogen protection by heating. After the reaction, it is purified to obtain an intermediate with the structure of formula (II) as follows.
[0019] S2, intermediate and R1NH2 reacted with a protic acid catalyst under heating. After the reaction, the reaction solution was cooled, the pH was adjusted to 7-8, concentrated and purified by column chromatography to obtain 2-aminopyrimidine compounds of general formula (I). (II).
[0020] Preferably, in step S1, the molar ratio of 2,4,5-trichloropyrimidine to R3-substituted benzenesulfonamide is (1-2):1, the base is N,N-diisopropylethylamine, anhydrous potassium carbonate or anhydrous cesium carbonate; the heating temperature is 70-100°C, and the reaction time is 3-12 h.
[0021] Preferably, in step S2, the molar ratio of the intermediate to R1NH2 is 1:(1-2), and the protic acid catalyst is trifluoroacetic acid, concentrated hydrochloric acid, or p-toluenesulfonic acid monohydrate.
[0022] Preferably, in step S2, the heating temperature is 60–80°C, the reaction time is 3–72 h, and the eluent used for column chromatography purification is petroleum ether and ethyl acetate in a volume ratio of (1–9):(1–3).
[0023] The present invention also provides the use of the 2-aminopyrimidine compounds or pharmaceutically acceptable salts thereof in the preparation of hematopoietic progenitor cell kinase 1 inhibitors.
[0024] The present invention also provides the use of the 2-aminopyrimidine compounds or pharmaceutically acceptable salts thereof in the preparation of medicaments for treating non-small cell lung cancer, acute T-lymphoblastic leukemia, B-cell lymphoma or acute monocytic leukemia.
[0025] The present invention has at least the following beneficial effects:
[0026] 1. Developing a Novel Compound Skeleton System: This invention provides a novel structural compound with a 2-aminopyrimidine core and characteristic side chains of benzenesulfonamide and diaryl ether. This molecular skeleton is significantly different from the chemical structures of existing HPK1 inhibitors, exhibiting extremely high structural novelty. Relying on a universal structural formula that is compatible with a wide range of substituent modifications, a complete molecular structure protection system covering the core skeleton and peripheral substituent modifications is constructed, providing a solid compound foundation for creating a class of innovative anti-tumor drugs with independent and original chemical structures.
[0027] 2. Achieving highly efficient transduction of molecular kinase activity to cellular efficacy, with significant advantages in cellular efficacy: Through systematic structure-activity analysis and iterative optimization of molecular structure, the series of compounds in this invention overcomes the technical challenge of synchronously converting molecular kinase activity and cellular efficacy, a common problem among inhibitors of this type. Compound PXW-5 not only maintains nanomolar-level potent target inhibition at the molecular level, but also exhibits significantly better anti-tumor proliferation effects at the cellular level than the control positive drug, fully demonstrating that this type of compound possesses excellent cell membrane permeability and highly efficient target binding ability.
[0028] 3. Establishing a complete and clear structure-activity relationship provides clear R&D guidance for subsequent molecular optimization: This invention is the first to clearly identify the R1 substitution site in this novel scaffold system as the key site for regulating target inhibitory activity, and innovatively proposes a molecular design criterion of "weak electron-donating and weak polarity" for the preferred substituent groups. This quantitative and clear design theory can support multi-dimensional structural modification of this series of compounds, including improving the ability to distinguish kinase subtypes and optimizing in vivo drug metabolism, effectively shortening the subsequent molecular iteration cycle and improving the success rate of candidate molecule development.
[0029] 4. Construction of a diverse compound library with multiple substitution types, possessing broad potential for subsequent development and application: Through efficient and highly regioselective synthetic processes, this invention completes the preparation and structural characterization of multi-substituted characteristic derivatives, constructing a compound library with rich molecular structures and diverse substituent types. This compound library can support large-scale screening, enabling the targeted acquisition of candidate drug molecules that possess high HPK1 subtype discrimination ability, low in vivo toxicity, and excellent pharmacokinetic parameters, thus providing sufficient material samples and experimental data for subsequent preclinical studies.
[0030] Other advantages, objectives and features of the present invention will become apparent in part from the following description, and in part from those skilled in the art through study and practice of the invention. Attached Figure Description
[0031] Figure 1 The image shows the 1H NMR spectrum of compound PXW-5 in Example 5 of this invention. Detailed Implementation
[0032] The present invention will now be described in further detail so that those skilled in the art can implement it based on the description.
[0033] It should be noted that, unless otherwise specified, the experimental methods described in the following implementation plan are all conventional methods, and the reagents and materials described are all commercially available unless otherwise specified.
[0034] Example 1
[0035] N-(5-chloro-2-((4-phenoxyphenyl)amino)pyrimidin-4-yl)-4-methylbenzenesulfonamide (PXW-1) has the following structure:
[0036]
[0037] Its synthetic route is as follows:
[0038]
[0039] The specific synthesis steps include:
[0040] Preparation of S1, N-(2,5-dichloropyrimidin-4-yl)-4-methylbenzenesulfonamide: 2,4,5-trichloropyrimidin (1.00 g) and p-toluenesulfonamide (0.84 g) were added to a 100 mL pressure-resistant reaction flask and dissolved completely in 25 mL of n-butanol. Then, N,N-diisopropylethylamine (DIPEA, 4 mL) was added dropwise. The system was purged with nitrogen to create an inert protective atmosphere, and the mixture was heated to 100 °C and stirred for 3 h. Thin-layer chromatography (TLC) was used (developing solvent: V...). DCM :V MeOH=10:1) Monitor the reaction progress. After the reaction is complete, allow the system to cool naturally to room temperature, and slowly add 25 mL of pre-cooled deionized water at 0℃, stirring continuously for 30 min to induce crystallization; allow to stand and separate, collect the organic phase and concentrate under reduced pressure to remove the solvent, and purify the crude product by silica gel column chromatography (eluent: V). PE :V EA The reaction ratio was 10:1, yielding 1.30 g of the target product N-(2,5-dichloropyrimidin-4-yl)-4-methylbenzenesulfonamide as a off-white solid powder, with a reaction yield of 85%. Characterization data: 1 H NMR (400 MHz, DMSO-d6) δ 11.38 (brs, 1H), 7.84 (d, J = 7.5 Hz, 2H), 7.38 (s, 1H), 7.34 (d, J = 7.5 Hz, 2H), 2.43 (s, 3H). 13 C NMR (101 MHz, DMSO-d6) δ 159.2, 158.7, 158.0, 137.6, 137.0, 129.3, 129.3, 128.3, 128.3,113.5, 21.3. HRMS (ESI-MS) m / z: [M+H] + calcd for C 11 H9Cl2N3O2S: 316.9793, found: 316.9795.
[0041] Preparation of S2 and N-(5-chloro-2-((4-phenoxyphenyl)amino)pyrimidin-4-yl)-4-methylbenzenesulfonamide (PXW-1): Take a 50 mL reaction flask, add intermediates N-(2,5-dichloropyrimidin-4-yl)-4-methylbenzenesulfonamide (500 mg) and 4-phenoxyaniline (320 mg) sequentially, add trifluoroacetic acid (200 μL), and then add isopropanol (10 mL) as the reaction solvent; after nitrogen purging protection, heat to 80℃ and maintain the reaction temperature for 4 h. Thin-layer chromatography (TLC) is performed (developing solvent: V... DCM V MeOH = 20:1) Track the reaction endpoint. Cool the reaction solution to room temperature, slowly add triethylamine to adjust the pH of the system to 7-8, then concentrate under reduced pressure to remove the solvent to obtain the crude product; the crude product is purified by silica gel column chromatography (eluent: V PE :V EA (The ratio of the two compounds was 9:1), and after purification, the target compound PXW-1 was obtained, with a yield of 35% for this step. 1H NMR (400 MHz, CDCl3) δ 11.56 (s, 1H), 9.05 (s, 1H), 8.10 (s, 1H), 7.85 (d, J = 8.1 Hz, 2H), 7.52 (d, J = 8.9 Hz, 2H), 7.39 – 7.33 (m,2H), 7.20 (d, J = 8.1 Hz, 2H), 7.12-7.03 (m, 5H), 2.40 (s, 3H). 13 C NMR (101MHz, DMSO-d6) δ 154.25, 139.58, 138.04, 133.04, 131.47, 129.22, 128.64, 124.23,113.03, 22.58. HRMS (ESI-MS) m / z:[M+H] + calcd for C 23 H 19 ClN4O3S: 467.0944, found: 467.0947.
[0042] Example 2
[0043] N-(5-chloro-2-((4-(p-tolyloxy)phenyl)amino)pyrimidin-4-yl)-4-methylbenzenesulfonamide (PXW-2) has the following structure:
[0044]
[0045] Its synthetic route is as follows:
[0046]
[0047] The specific synthesis steps include:
[0048] Preparation of S1, N-(2,5-dichloropyrimidin-4-yl)-4-methylbenzenesulfonamide: Same as step S1 in Example 1.
[0049] Preparation of S2 and N-(5-chloro-2-((4-(p-tolyloxy)phenyl)amino)pyrimidin-4-yl)-4-methylbenzenesulfonamide (PXW-2): Take a 50 mL reaction flask, add intermediates N-(2,5-dichloropyrimidin-4-yl)-4-methylbenzenesulfonamide (500 mg) and 4-(p-tolyloxy)aniline (375 mg) sequentially, add trifluoroacetic acid (200 μL), and then add isopropanol (12 mL) as the reaction solvent; after nitrogen purging protection, heat to 80℃ and maintain the reaction temperature for 6 h. Thin-layer chromatography (TLC) (developing solvent: V...) DCM V MeOH= 20:1) Track the reaction endpoint. Cool the reaction solution to room temperature, slowly add triethylamine to adjust the pH of the system to 7-8, then concentrate under reduced pressure to remove the solvent to obtain the crude product; the crude product is purified by silica gel column chromatography (eluent: V PE :V EA (The ratio of the two compounds is 9:1), and after purification, the target compound PXW-2 was obtained, with a yield of 60% for this step. 1 H NMR (400 MHz, DMSO-d6) δ 8.17 (s, 1H), 8.09 (s,1H), 7.28 (d, J = 8.2 Hz, 2H), 7.00 (d, J = 7.5 Hz, 2H), 6.97-6.87 (m, 9H), 2.39 (s, 3H), 2.08 (s, 3H). 13 C NMR (101MHz, DMSO-d6) δ 157.52, 155.13, 149.07,145.87, 134.63, 132.74, 130.18, 122.81, 121.12, 120.03, 118.14, 115.32,21.43, 20.58.. HRMS(ESI-MS)m / z:[M+Na] + calcd for C 24 H 21 ClN4O3S: 503.0922, found:503.0917.
[0050] Example 3
[0051]
[0052] Its synthetic route is as follows:
[0053]
[0054] The specific synthesis steps include:
[0055] Preparation of S1, N-(2,5-dichloropyrimidin-4-yl)-4-methylbenzenesulfonamide: Same as step S1 in Example 1.
[0056] Preparation of S2, N-(5-chloro-2-((4-(4-methoxyphenoxy)phenyl)amino)pyrimidin-4-yl)-4-methylbenzenesulfonamide (PXW-3): Take a 50 mL reaction flask, add intermediates N-(2,5-dichloropyrimidin-4-yl)-4-methylbenzenesulfonamide (500 mg) and 4-(4-methoxyphenoxy)aniline (405 mg) sequentially, add trifluoroacetic acid (168 μL), and then add isopropanol (12 mL) as the reaction solvent; after nitrogen purging protection, heat to 80℃ and maintain the reaction temperature for 6 h. Thin-layer chromatography (TLC) (developing solvent: V...) DCM :V MeOH =20:1) Track the reaction endpoint. Cool the reaction solution to room temperature, slowly add triethylamine to adjust the pH of the system to 7-8, then concentrate under reduced pressure to remove the solvent to obtain the crude product; the crude product is purified by silica gel column chromatography (eluent: V PE :V EA (The ratio of the two compounds was 9:1), and after purification, the target compound PXW-3 was obtained, with a yield of 55% for this step. 1 H NMR (400 MHz, DMSO-d6) δ 10.52 (s,1H), 9.82 (s, 1H), 8.16 (s, 1H), 7.75 (d, J = 7.7 Hz, 2H), 7.60-7.53 (m, 2H),7.19 (d, J = 7.8 Hz, 2H), 6.99-6.94 (m, 4H), 6.90-6.85 (m, 2H), 3.75 (s, 3H), 2.30 (s, 3H). 13 C NMR (101MHz, DMSO-d6) δ 157.25, 150.68, 129.36, 127.49,122.12, 120.54, 118.35, 115.54, 55.94, 21.40. HRMS (ESI-MS) m / z:[M+H] + calcdfor C 24 H 21 ClN4O4S: 497.1050, found: 497.1052.
[0057] Example 4
[0058] N-(5-chloro-2-((4-phenoxyphenyl)amino)pyrimidin-4-yl)-4-methoxybenzenesulfonamide (PXW-4) has the following structure:
[0059]
[0060] Its synthetic route is as follows:
[0061]
[0062] The specific synthesis steps include:
[0063] Preparation of S1, N-(2,5-dichloropyrimidin-4-yl)-4-methoxybenzenesulfonamide: 2,4,5-trichloropyrimidin (1.00 g) and 4-methoxybenzenesulfonamide (0.92 g), anhydrous potassium carbonate (3.01 g), were added to a 100 mL pressure-resistant reaction flask and dissolved in acetonitrile (15 mL). The system was purged with nitrogen to create an inert protective atmosphere, and the mixture was heated to 72 °C and stirred for 6 h. Thin-layer chromatography (TLC) was used (developing solvent: V...). DCM :V MeOH =20:1) Monitor the reaction progress. After the reaction is complete, allow the system to cool naturally to room temperature, concentrate under reduced pressure to remove the solvent, and purify the crude product by silica gel column chromatography (eluent: V). PE :V EA =3:1), yielding a yellowish-brown solid powder product N-(2,5-dichloropyrimidin-4-yl)-4-methoxybenzenesulfonamide (1.49 g, yield 91%). Characterization data: 1 H NMR (400MHz, DMSO-d6) δ 11.30 (brs, 1H), 7.55 (d, J = 7.5 Hz, 2H), 7.38 (s, 1H), 7.06 (d, J = 7.5 Hz, 2H), 3.81 (s, 3H). 13 C NMR (101 MHz, DMSO-d6) δ 164.0, 159.3,158.6, 158.2, 132.5, 126.1, 126.1, 114.5, 114.5, 113.8, 55.8. HRMS (ESI-MS)m / z: [M+H] + calcd for C 11 H9Cl2N3O3S: 332.9742, found: 332.9747.
[0064] Preparation of S2 and N-(5-chloro-2-((4-phenoxyphenyl)amino)pyrimidin-4-yl)-4-methoxybenzenesulfonamide (PXW-4): Take a 50 mL reaction flask, add intermediates N-(2,5-dichloropyrimidin-4-yl)-4-methoxybenzenesulfonamide (500 mg) and 4-phenoxyaniline (333 mg) sequentially, add trifluoroacetic acid (160 μL), and then add isopropanol (12 mL) as the reaction solvent; after nitrogen purging protection, raise the temperature to 80℃ and maintain the reaction for 10 h. Thin-layer chromatography (TLC) (developing solvent: V...) DCM :VMeOH =15:1) Track the reaction endpoint. Cool the reaction solution to room temperature, slowly add triethylamine to adjust the pH of the system to 7-8, then concentrate under reduced pressure to remove the solvent to obtain the crude product; the crude product is purified by silica gel column chromatography (eluent: V PE :V EA (The ratio of the two compounds was 9:1), and after purification, the target compound PXW-4 was obtained, with a yield of 60% for this step.
[0065] 1 H NMR (400 MHz, DMSO-d6) δ 11.39 (s, 1H), 8.10 (s, 1H), 7.85 (d, J =8.1 Hz, 2H), 7.52 (d, J = 8.9 Hz, 2H), 7.36 (dd, J = 8.6, 7.3 Hz, 2H), 7.20(d, J = 8.1 Hz, 2H), 7.14 -7.02 (m, 6H), 3.83 (s, 3H). 13 C NMR (101MHz, DMSO-d6) δ 159.45, 145.98, 145.94, 130.12, 122.18, 121.37, 116.89, 115.35. HRMS (ESI-MS) m / z: [M+Na] + calcd for C 23 H 19 ClN4O4S: 505.0715, found: 505.0720.
[0066] Example 5
[0067] N-(5-chloro-2-((4-(p-tolyloxy)phenyl)amino)pyrimidin-4-yl)-4-methoxybenzenesulfonamide (PXW-5) has the following structure:
[0068]
[0069] Its synthetic route is as follows:
[0070]
[0071] The specific synthesis steps include:
[0072] Preparation of S1, N-(2,5-dichloropyrimidin-4-yl)-4-methoxybenzenesulfonamide: Same as step S1 in Example 4.
[0073] Preparation of S2 and N-(5-chloro-2-((4-(p-tolyloxy)phenyl)amino)pyrimidin-4-yl)-4-methoxybenzenesulfonamide (PXW-5): Take a 50 mL reaction flask, add intermediates N-(2,5-dichloropyrimidin-4-yl)-4-methoxybenzenesulfonamide (500 mg) and 4-(p-tolyloxy)aniline (359 mg) sequentially, add trifluoroacetic acid (400 μL), and then add isopropanol (12 mL) as the reaction solvent; after nitrogen purging protection, heat to 65℃ and maintain the reaction for 12 h. Thin-layer chromatography (TLC) (developing solvent: V...) DCM :V MeOH =15:1) Track the reaction endpoint. Cool the reaction solution to room temperature, slowly add triethylamine to adjust the pH of the system to 7-8, then concentrate under reduced pressure to remove the solvent to obtain the crude product; the crude product is purified by silica gel column chromatography (eluent: V PE :V EA The ratio of the target compound to the target compound PXW-5 was 7:1. After purification, the compound was obtained with a yield of 25.1%. The 1H NMR spectrum of compound PXW-5 is shown below. Figure 1 As shown, the specific characterization data is as follows: 1 H NMR (400 MHz, DMSO-d6) δ 11.23 (s, 1H), 8.35 (s, 1H), 7.68-7.63 (m,4H), 7.18 (s, 1H), 7.03-7.00 (m, 4H), 6.93-6.91 (m, 4H), 4.00 (s, 3H), 2.29(s, 3H). 13 C NMR (101MHz, DMSO-d6) δ 163.48, 157.31, 151.09, 145.91, 132.79,131.82, 130.22, 122.01, 120.35, 118.87, 116.34, 115.33, 56.11, 20.59. HRMS(ESI-MS) m / z:[M+H] + calcd for C 24 H 21 ClN4O4S: 497.1050, found: 497.1056.
[0074] Example 6
[0075] N-(5-chloro-2-((4-(4-methoxyphenoxy)phenyl)amino)pyrimidin-4-yl)-4-methoxybenzenesulfonamide (PXW-6) has the following structure:
[0076]
[0077] Its synthetic route is as follows:
[0078]
[0079] The specific synthesis steps include:
[0080] Preparation of S1, N-(2,5-dichloropyrimidin-4-yl)-4-methoxybenzenesulfonamide: Same as step S1 in Example 4.
[0081] Preparation of S2, N-(5-chloro-2-((4-(4-methoxyphenoxy)phenyl)amino)pyrimidin-4-yl)-4-methoxybenzenesulfonamide (PXW-6): Take a 50 mL reaction flask, add intermediates N-(2,5-dichloropyrimidin-4-yl)-4-methoxybenzenesulfonamide (500 mg) and 4-(4-methoxyphenoxy)aniline (387 mg) sequentially, add trifluoroacetic acid (343 μL), and then add isopropanol (12 mL) as the reaction solvent; after nitrogen purging protection, raise the temperature to 75℃ and maintain the reaction for 12 h. Thin-layer chromatography (TLC) (developing solvent: V...) DCM :V MeOH =15:1) Track the reaction endpoint. Cool the reaction solution to room temperature, slowly add triethylamine to adjust the pH of the system to 7-8, then concentrate under reduced pressure to remove the solvent to obtain the crude product; the crude product is purified by silica gel column chromatography (eluent: V PE :V EA (7:1), after purification, the target compound PXW-6 was obtained, with a yield of 30% for this step. 1 H NMR (400 MHz, DMSO-d6) δ 11.20(s, 1H), 8.86 (s, 1H), 7.63 (d, J = 8.9 Hz, 4H), 7.26 (s, 2H), 7.08 (s, 1H),7.07 (s, 4H), 6.99 (s, 2H), 3.75 (s, 6H). 13 C NMR (101MHz, DMSO-d6) δ 154.90,152.63, 147.57, 145.32, 120.37, 118.74, 115.32, 115.24, 55.85. HRMS (ESI-MS)m / z: [M+Na] + calcd for C 24 H 21 ClN4O5S: 535.0819, found: 535.0822.
[0082] Example 7
[0083] 4-tert-butyl-N-(5-chloro-2-((4-phenoxyphenyl)amino)pyrimidin-4-yl)benzenesulfonamide (PXW-7) has the following structure:
[0084]
[0085] Its synthetic route is as follows:
[0086]
[0087] The specific synthesis steps include:
[0088] Preparation of S1, 4-tert-butyl-N-(2,5-dichloropyrimidin-4-yl)benzenesulfonamide: 2,4,5-trichloropyrimidin (1.00 g) and 4-tert-butylbenzenesulfonamide (1.05 g), anhydrous potassium carbonate (3.01 g), were added to a 100 mL pressure-resistant reaction flask and dissolved in acetonitrile (15 mL). The system was purged with nitrogen to create an inert protective atmosphere, and the temperature was raised to 80 °C and stirred for 6 h. Thin-layer chromatography (TLC) was used (developing solvent: V... DCM :V MeOH =10:1) Monitor the reaction progress. After the reaction is complete, allow the system to cool naturally to room temperature, concentrate under reduced pressure to remove the solvent, and purify the crude product by silica gel column chromatography (eluent: V). PE :V EA =1:1), yielding a yellowish-brown solid powder product, 4-tert-butyl-N-(2,5-dichloropyrimidin-4-yl)benzenesulfonamide (1.470 g, yield 82.9%). Characterization data: 1 H NMR (400MHz, DMSO-d6) δ 11.38 (brs, 1H), 7.65 (d, J = 7.5 Hz, 2H), 7.56 (d, J = 7.5Hz, 2H), 7.38 (s, 1H), 1.33 (s, 9H). 13 HRMS (ESI-MS) m / z: [M+H] + calcd for C 14 H 15 Cl2N3O2S: 359.0262, found:359.0264.
[0089] Preparation of S2, 4-tert-butyl-N-(5-chloro-2-((4-phenoxyphenyl)amino)pyrimidin-4-yl)benzenesulfonamide (PXW-7): Take a 50 mL reaction flask, add intermediate 4-tert-butyl-N-(2,5-dichloropyrimidin-4-yl)benzenesulfonamide (500 mg) and 4-phenoxyaniline (309 mg) sequentially, add trifluoroacetic acid (155 μL), and then add isopropanol (12 mL) as the reaction solvent; after nitrogen purging protection, heat to 75℃ and maintain the reaction temperature for 3 h. Thin-layer chromatography (TLC) (developing solvent: V...) DCM :V MeOH =10:1) Track the reaction endpoint. Cool the reaction solution to room temperature, slowly add triethylamine to adjust the pH of the system to 7-8, then concentrate under reduced pressure to remove the solvent to obtain the crude product; the crude product is purified by silica gel column chromatography (eluent: V PE :V EA The ratio of the two compounds was 8:1. After purification, the target compound PXW-7 was obtained, with a yield of 18% for this step. 1 H NMR (400 MHz, DMSO-d6) δ 11.25 (s, 1H), 8.87 (s, 1H), 7.77 (d, J = 8.3 Hz, 2H), 7.42-7.36 (m, 6H), 7.21 (s, 1H), 7.19 (s, 1H), 7.07(d, J = 2.5 Hz, 2H), 6.95 (d, J = 1.4 Hz, 2H), 1.21 (s, 9H). 13 C NMR (101MHz, DMSO-d6) δ 158.86, 158.55, 158.30, 155.20, 151.15, 130.39, 128.99, 123.13,121.68, 119.88, 117.99, 116.60, 116.20, 34.41. HRMS (ESI-MS) m / z:[M+H] + calcdfor C 26 H 25 ClN4O3S: 509.1414, found: 509.1404.
[0090] Example 8
[0091] 4-tert-butyl-N-(5-chloro-2-((4-(p-tolyloxy)phenyl)amino)pyrimidin-4-yl)benzenesulfonamide (PXW-8) has the following structure:
[0092]
[0093] Its synthetic route is as follows:
[0094]
[0095] The specific synthesis steps include:
[0096] Preparation of S1, 4-tert-butyl-N-(2,5-dichloropyrimidin-4-yl)benzenesulfonamide: Same as step S1 in Example 7.
[0097] Preparation of S2, 4-tert-butyl-N-(5-chloro-2-((4-(p-tolyloxy)phenyl)amino)pyrimidin-4-yl)benzenesulfonamide (PXW-8): Take a 50 mL reaction flask, add intermediates 4-tert-butyl-N-(2,5-dichloropyrimidin-4-yl)benzenesulfonamide (500 mg) and 4-(p-tolyloxy)aniline (332 mg) sequentially, add trifluoroacetic acid (418 μL), and then add isopropanol (14 mL) as the reaction solvent; after nitrogen purging protection, heat to 65℃ and maintain the reaction temperature for 3 h. Thin-layer chromatography (TLC) (developing solvent: V...) DCM :V MeOH =10:1) Track the reaction endpoint. Cool the reaction solution to room temperature, slowly add triethylamine to adjust the pH of the system to 7-8, then concentrate under reduced pressure to remove the solvent to obtain the crude product; the crude product is purified by silica gel column chromatography (eluent: V PE :V EA The ratio of the target compound to the target compound PXW-8 was 8:1. After purification, the compound was obtained with a yield of 18%. 1 H NMR (400 MHz, DMSO-d6) δ 11.22 (s, 1H), 9.59 (s, 1H), 7.64 (d, J = 8.8 Hz, 2H), 7.28 (d, J = 7.9 Hz, 4H), 7.21 (s,1H), 7.01 (d, J = 8.9 Hz, 2H), 6.93 (s, 2H), 6.90 (s, 2H), 2.29 (s, 3H), 1.23(s, 9H). 13 C NMR (101MHz, DMSO-d6) δ 158.54, 156.41, 154.42, 146.59, 145.75, 134.11, 132.58, 130.29, 127.23, 120.11, 117.08, 115.41, 35.19, 31.18, 20.58.HRMS (ESI-MS) m / z:[M+Na] + calcd for C 27 H 27ClN4O3S: 545.1390, found: 545.1389.
[0098] Example 9
[0099] 4-tert-butyl-N-(5-chloro-2-((4-(4-methoxyphenoxy)phenyl)amino)pyrimidin-4-yl)benzenesulfonamide (PXW-9) has the following structure:
[0100]
[0101] Its synthetic route is as follows:
[0102]
[0103] The specific synthesis steps include:
[0104] Preparation of S1, 4-tert-butyl-N-(2,5-dichloropyrimidin-4-yl)benzenesulfonamide: Same as step S1 in Example 7.
[0105] Preparation of S2, 4-tert-butyl-N-(5-chloro-2-((4-(4-methoxyphenoxy)phenyl)amino)pyrimidin-4-yl)benzenesulfonamide (PXW-9): In a 50 mL reaction flask, intermediates 4-tert-butyl-N-(2,5-dichloropyrimidin-4-yl)benzenesulfonamide (500 mg) and 4-(4-methoxyphenoxy)aniline (359 mg) were added sequentially. Trifluoroacetic acid (348 μL) was added, followed by isopropanol (12 mL) as the reaction solvent. After nitrogen purging, the temperature was raised to 60 °C and maintained for 3.5 h. Thin-layer chromatography (TLC) was performed (developing solvent: V...). DCM :V MeOH =10:1) Track the reaction endpoint. Cool the reaction solution to room temperature, slowly add triethylamine to adjust the pH of the system to 7-8, then concentrate under reduced pressure to remove the solvent to obtain the crude product; the crude product is purified by silica gel column chromatography (eluent: V PE :V EA The ratio of the two compounds was 8:1. After purification, the target compound PXW-9 was obtained, with a yield of 16% for this step. 1 H NMR (400 MHz, DMSO-d6) δ 11.20(s, 1H), 8.85 (s, 1H), 7.62 (d, J = 9.0 Hz, 1H), 7.10-7.03 (m, 2H), 7.01-6.94(m, 4H), 6.76 (s, 1H), 6.74 (d, J = 2.7 Hz, 2H), 6.64-6.60 (m, 2H), 6.51-6.49(m, 1H), 3.75 (s, 3H), 1.24 (s, 9H).13 C NMR (101MHz, DMSO-d6) δ 158.52, 156.68,154.44, 152.91, 147.87, 145.53, 134.15, 127.31, 120.57, 119.17, 115.62,115.21, 55.89, 35.18, 31.16. HRMS (ESI-MS) m / z:[M+H] + calcd for C 27 H 27 ClN4O4S:539.1520, found: 539.1523.
[0106] Example 10
[0107] N-(4-(N-(5-chloro-2-((4-phenoxyphenyl)amino)pyrimidin-4-yl)aminosulfonyl)phenyl)acetamide (PXW-10) has the following structure:
[0108]
[0109] Its synthetic route is as follows:
[0110]
[0111] The specific synthesis steps include:
[0112] Preparation of S1, N-(4-(N-(2,5-dichloropyrimidin-4-yl)aminosulfonyl)phenyl)acetamide: 2,4,5-trichloropyrimidin (1.00 g) and N-(4-sulfonamidophenyl)acetamide (1.05 g), anhydrous cesium carbonate (2.66 g), were added to a 100 mL pressure-resistant reaction flask and dissolved in acetonitrile (20 mL). The system was purged with nitrogen to create an inert protective atmosphere, and the mixture was heated to 80 °C and stirred for 10 h. Thin-layer chromatography (TLC) was used (developing solvent: V...). DCM :V MeOH =8:1) Monitor the reaction progress. After the reaction is complete, allow the system to cool naturally to room temperature, concentrate under reduced pressure to remove the solvent, and purify the crude product by silica gel column chromatography (eluent: V). PE :V EA =1:1), yielding a yellowish-brown solid powder product N-(4-(N-(2,5-dichloropyrimidin-4-yl)aminosulfonyl)phenyl)acetamide (1.70 g, yield 85%). Characterization data: 1H NMR (400 MHz, DMSO-d6) δ 11.04 (brs, 1H), 10.20 (brs, 1H), 7.72 (d, J = 7.5 Hz, 2H), 7.68 (d, J = 7.5 Hz, 2H), 7.38 (s, 1H), 2.06 (s,3H). 13 C NMR (101 MHz, DMSO-d6) δ 169.0, 159.2, 158.7, 158.2, 145.0, 135.5,129.4, 129.4, 118.0, 118.0, 113.7, 24.0. HRMS (ESI-MS) m / z: [M+H] + calcd forC 12 H 10 Cl2N4O3S: 359.9851, found: 359.9855.
[0113] Preparation of S2, N-(4-(N-(5-chloro-2-((4-phenoxyphenyl)amino)pyrimidin-4-yl)aminosulfonyl)phenyl)acetamide (PXW-10): Take a 50 mL reaction flask, and add intermediates N-(4-(N-(2,5-dichloropyrimidin-4-yl)aminosulfonyl)phenyl)acetamide (500 mg) and 4-phenoxyaniline (306 mg) sequentially. Add trifluoroacetic acid (41 μL), and then add isopropanol (14 mL) as the reaction solvent. After nitrogen purging protection, raise the temperature to 80℃ and maintain the reaction for 12 h. Thin-layer chromatography (TLC) (developing solvent: V) DCM :V MeOH =9:1) Track the reaction endpoint. Cool the reaction solution to room temperature, slowly add triethylamine to adjust the pH of the system to 7-8, then concentrate under reduced pressure to remove the solvent to obtain the crude product; the crude product is purified by silica gel column chromatography (eluent: V PE :V EA The ratio of the two compounds was 6:1. After purification, the target compound PXW-10 was obtained, with a yield of 37% for this step. 1 H NMR (400 MHz, DMSO-d6) δ 10.99 (s,1H), 10.25 (s, 1H), 9.53 (s, 1H), 8.20 (s, 1H), 7.87 (s, 2H), 7.67 – 7.59 (m,4H), 7.39 (dd, J = 8.6, 7.3 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 7.00 (dd, J =8.4, 5.4 Hz, 4H), 2.05 (s, 3H).13 C NMR (101MHz, DMSO-d6) δ 169.43, 158.12,151.81, 143.56, 130.43, 129.29, 123.30, 122.27, 120.49, 119.90, 118.40,118.12, 24.58. HRMS (ESI-MS) m / z:[M+H] + calcd for C 24 H 20 ClN5O4S: 510.1003, found: 510.1003.
[0114] Example 11
[0115] N-(4-(N-(5-chloro-2-((4-(p-tolyloxy)phenyl)amino)pyrimidin-4-yl)aminosulfonyl)phenyl)acetamide (PXW-11) has the following structure:
[0116]
[0117] Its synthetic route is as follows:
[0118]
[0119] The specific synthesis steps include:
[0120] Preparation of S1, N-(4-(N-(2,5-dichloropyrimidin-4-yl)aminosulfonyl)phenyl)acetamide: Same as step S1 in Example 10.
[0121] Preparation of S2, N-(4-(N-(5-chloro-2-((4-(p-tolyloxy)phenyl)amino)pyrimidin-4-yl)aminosulfonyl)phenyl)acetamide (PXW-11): Take a 50 mL reaction flask, add intermediates N-(4-(N-(2,5-dichloropyrimidin-4-yl)aminosulfonyl)phenyl)acetamide (500 mg) and 4-(p-tolyloxy)aniline (330 mg) sequentially, add trifluoroacetic acid (175 μL), and then add isopropanol (12 mL) as the reaction solvent; after nitrogen purging protection, heat to 80℃ and maintain the reaction temperature for 4 h. Thin-layer chromatography (TLC) (developing solvent: V) DCM :V MeOH =9:1) Track the reaction endpoint. Cool the reaction solution to room temperature, slowly add triethylamine to adjust the pH of the system to 7-8, then concentrate under reduced pressure to remove the solvent to obtain the crude product; the crude product is purified by silica gel column chromatography (eluent: V PE :V EA (The ratio of the two compounds was 6:1), and after purification, the target compound PXW-11 was obtained, with a yield of 36% for this step.1 H NMR (400 MHz, DMSO-d6)δ 11.22 (s, 1H), 8.70 (s, 1H), 7.64 (d, J = 8.8 Hz, 2H), 7.28 (d, J = 8.2 Hz, 2H), 7.20 (d, J = 8.3 Hz, 2H), 7.00 (d, J = 8.6 Hz, 2H), 6.96 (d, J = 3.2 Hz,2H), 6.93 (s, 1H), 6.90 (s, 1H), 6.88 (s, 1H), 2.39 (s, 3H), 2.08 (s, 3H). 13 CNMR (101MHz, DMSO-d6) δ 169.21, 157.35, 153.18, 146.62, 145.69, 144.52, 133.44,131.29, 130.47, 121.02, 117.12, 115.38, 24.51, 20.58. HRMS (ESI-MS) m / z: [M+Na] + calcd for C 25 H 22 ClN5O4S: 546.0979, found: 546.0977.
[0122] Example 12
[0123] N-(4-(N-(5-chloro-2-((4-(4-(4-methoxyphenoxy)phenyl)amino)pyrimidin-4-yl)aminosulfonyl)phenyl)acetamide (PXW-12) has the following structure:
[0124]
[0125] Its synthetic route is as follows:
[0126]
[0127] The specific synthesis steps include:
[0128] Preparation of S1, N-(4-(N-(2,5-dichloropyrimidin-4-yl)aminosulfonyl)phenyl)acetamide: Same as step S1 in Example 10.
[0129] Preparation of S2, N-(4-(N-(5-chloro-2-((4-(4-(4-methoxyphenoxy)phenyl)amino)pyrimidin-4-yl)aminosulfonyl)phenyl)acetamide (PXW-12): Take a 50 mL reaction flask, and add intermediates N-(4-(N-(2,5-dichloropyrimidin-4-yl)aminosulfonyl)phenyl)acetamide (500 mg) and 4-(4-methoxyphenoxy)aniline (357 mg) sequentially. Add trifluoroacetic acid (41 μL), and then add isopropanol (12 mL) as the reaction solvent. After nitrogen purging protection, heat to 70℃ and maintain the reaction temperature for 8 h. Thin-layer chromatography (TLC) (developing solvent: V) DCM :V MeOH =8:1) Track the reaction endpoint. Cool the reaction solution to room temperature, slowly add triethylamine to adjust the pH of the system to 7-8, then concentrate under reduced pressure to remove the solvent and obtain the crude product; the crude product is purified by silica gel column chromatography (eluent: V PE :V EA (The ratio of the two compounds is 3:1), and after purification, the target compound PXW-12 was obtained, with a yield of 31% for this step. 1 H NMR (400 MHz, DMSO-d6) δ 10.27 (s, 1H), 9.97 (s, 1H), 9.54 (s, 1H), 7.75-7.68 (m, 4H), 7.60 (s, 3H), 6.97 (d, J = 1.5 Hz, 4H), 6.93-6.89 (m, 2H), 3.74 (s, 3H), 2.05 (s, 3H). 13 C NMR (101MHz, DMSO-d6) δ 169.42, 155.75, 150.90, 144.53, 138.39,132.52, 131.39, 130.37, 129.72, 129.02, 128.93, 122.34, 120.28, 118.60,118.50, 118.46, 118.37, 115.53, 55.88, 24.56. HRMS (ESI-MS) m / z:[M+H] + calcdfor C 25 H 22 ClN5O5S: 540.1108, found: 540.1107.
[0130] Example 13
[0131] N-(5-chloro-2-((4-phenoxyphenyl)amino)pyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide (PXW-13) has the following structure:
[0132]
[0133] Its synthetic route is as follows:
[0134]
[0135] The specific synthesis steps include:
[0136] Preparation of S1, N-(2,5-dichloropyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide: 2,4,5-trichloropyrimidin (1.00 g) and 4-(3-ethylureo)benzenesulfonamide (1.19 g), anhydrous cesium carbonate (2.66 g), were added to a 100 mL pressure-resistant reaction flask and dissolved in DMSO (10 mL) and acetonitrile (10 mL). The system was purged with nitrogen to create an inert protective atmosphere, and the temperature was raised to 80 °C and stirred for 12 h. Thin-layer chromatography (TLC) was used (developing solvent: V...). DCM :V MeOH =7:1) Monitor the reaction progress. After the reaction is complete, allow the system to cool naturally to room temperature, concentrate under reduced pressure to remove the solvent, and purify the crude product by silica gel column chromatography (eluent: V). PE :V EA =1:5), yielding a white solid powder, N-(2,5-dichloropyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide (1.18 g, yield 55%). Characterization data: 1 H NMR (400 MHz, DMSO-d6) δ 11.04 (brs, 1H, SO2NH), 8.34 (brs, 1H), 7.72 (d, J = 7.5 Hz, 2H), 7.64 (d, J = 7.5 Hz, 2H), 7.38 (s, 1H), 6.02 (brs, 1H), 3.24 (q, J = 8.0 Hz, 2H), 1.04 (t, J = 8.0 Hz, 3H). 13 C NMR (101 MHz, DMSO-d6) δ 158.8, 158.5, 158.3, 154.5, 142.5, 135.0, 129.4, 129.4,118.0, 118.0, 113.5, 34.5, 14.5. HRMS (ESI-MS) m / z: [M+H] + calcd forC 13 H 13 Cl2N5O3S: 389.0116, found: 389.0122.
[0137] Preparation of S2 and N-(5-chloro-2-((4-phenoxyphenyl)amino)pyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide (PXW-13): Take a 50 mL reaction flask, add intermediates N-(2,5-dichloropyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide (500 mg) and 4-phenoxyaniline (285 mg) sequentially, add trifluoroacetic acid (137 μL), then add isopropanol (10 mL) and DMSO (2 mL) as reaction solvents; after nitrogen purging protection, heat to 70℃ and maintain the reaction temperature for 8 h. Thin-layer chromatography (TLC) (developing solvent: V...) DCM :V MeOH =9:1) Track the reaction endpoint. Cool the reaction solution to room temperature, slowly add triethylamine to adjust the pH of the system to 7-8, then concentrate under reduced pressure to remove the solvent to obtain the crude product; the crude product is purified by silica gel column chromatography (eluent: V PE :V EA The ratio of the two compounds was 3:1. After purification, the target compound PXW-13 was obtained, with a yield of 32% for this step. 1 H NMR (400 MHz, DMSO-d6) δ 9.38(s, 1H), 8.91 (s, 1H), 8.09 (s, 1H), 7.79-7.72 (m, 2H), 7.72-7.66 (m, 2H),7.41-7.35 (m, 4H), 7.17 (s, 2H), 7.08 (s, 1H), 6.97 (d, J = 2.2 Hz, 2H), 6.35(t, J = 5.6 Hz, 1H), 3.12-3.06 (m, 2H), 1.03 (t, J = 7.2 Hz, 3H). 13 C NMR (101MHz, DMSO-d6) δ 158.86, 158.55, 158.30, 155.20, 151.15, 130.39, 128.99,123.13, 121.68, 119.88, 117.99, 116.60, 116.20, 34.41, 15.73. HRMS (ESI-MS) m / z:[M+H] + calcd for C 25 H 23 ClN6O4S: 539.1268, found: 539.1271.
[0138] Example 14
[0139] N-(5-chloro-2-((4-(p-tolyloxy)phenyl)amino)pyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide (PXW-14) has the following structure:
[0140]
[0141] Its synthetic route is as follows:
[0142]
[0143] The specific synthesis steps include:
[0144] Preparation of S1, N-(2,5-dichloropyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide: Same as step S1 in Example 13.
[0145] Preparation of S2, N-(5-chloro-2-((4-(p-tolyloxy)phenyl)amino)pyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide (PXW-14): Take a 50 mL reaction flask, add intermediates N-(2,5-dichloropyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide (500 mg) and 4-(p-tolyloxy)aniline (306 mg) sequentially, add trifluoroacetic acid (137 μL), and then add isopropanol (12 mL) as the reaction solvent; after nitrogen purging protection, heat to 80℃ and maintain the reaction temperature for 8 h. Thin-layer chromatography (TLC) (developing solvent: V...) DCM :V MeOH =9:1) Track the reaction endpoint. Cool the reaction solution to room temperature, slowly add triethylamine to adjust the pH of the system to 7-8, then concentrate under reduced pressure to remove the solvent to obtain the crude product; the crude product is purified by silica gel column chromatography (eluent: V PE :V EA The ratio of the two compounds was 3:1. After purification, the target compound PXW-14 was obtained, with a yield of 21% for this step. 1H NMR (400 MHz, DMSO-d6) δ 9.50(s, 1H), 8.86 (s, 1H), 8.19 (s, 1H), 7.80 (d, J = 8.6 Hz, 2H), 7.67-7.60 (m,2H), 7.42 (d, J = 8.6 Hz, 2H), 7.23-7.15 (m, 2H), 7.00-6.86 (m, 4H), 6.80(dtd, J = 9.0, 6.3, 2.6 Hz, 1H), 6.25 (t, J = 5.6 Hz, 1H), 3.10 (qd, J = 7.2,5.4 Hz, 2H), 2.28 (s, 3H), 1.04 (t, J = 7.2 Hz, 3H). 13 C NMR (101MHz, DMSO-d6)δ 155.73, 155.03, 152.33, 145.25, 135.35, 132.38, 130.78, 130.61, 129.44,122.18, 120.55, 119.36, 118.38, 117.93, 117.77, 116.75, 34.46, 20.68, 20.62,15.74. HRMS (ESI-MS) m / z: [M+H] + calcd for C 26 H 25 ClN6O4S: 553.1425, found:553.1427.
[0146] Example 15
[0147] N-(5-chloro-2-((4-(4-methoxyphenoxy)phenyl)amino)pyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide (PXW-15) has the following structure:
[0148]
[0149] Its synthetic route is as follows:
[0150]
[0151] The specific synthesis steps include:
[0152] Preparation of S1, N-(2,5-dichloropyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide: Same as step S1 in Example 13.
[0153] Preparation of S2, N-(5-chloro-2-((4-(4-methoxyphenoxy)phenyl)amino)pyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide (PXW-15): Take a 50 mL reaction flask, add intermediates N-(2,5-dichloropyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide (500 mg) and 4-(4-methoxyphenoxy)aniline (331 mg) sequentially, add trifluoroacetic acid (438 μL), and then add isopropanol (12 mL) as the reaction solvent; after nitrogen purging protection, heat to 80℃ and maintain the reaction temperature for 8 h. Thin-layer chromatography (TLC) (developing solvent: V...) DCM :V MeOH =9:1) Track the reaction endpoint. Cool the reaction solution to room temperature, slowly add triethylamine to adjust the pH of the system to 7-8, then concentrate under reduced pressure to remove the solvent to obtain the crude product; the crude product is purified by silica gel column chromatography (eluent: V PE :V EA The ratio of the two compounds was 3:1. After purification, the target compound PXW-15 was obtained, with a yield of 17% for this step. 1 H NMR (400 MHz, DMSO-d6) δ 10.39 (s, 1H), 9.62 (s, 1H), 9.08 (s, 1H), 8.15 (s, 1H), 7.78 - 7.72(m, 2H), 7.66 - 7.60 (m, 2H), 7.42 - 7.36 (m, 2H), 7.00 - 6.88 (m, 6H), 6.34 (t, J = 5.6 Hz, 1H), 3.74 (s, 3H), 3.18 - 3.10 (m, 2H), 1.05 (t, J = 7.2 Hz, 3H). 13 C NMR (101MHz, DMSO-d6) δ 165.70, 158.10, 155.50, 152.60, 148.90, 144.30,135.70, 132.50, 129.20, 122.60, 121.90, 120.50, 118.90, 115.80, 115.50,56.00, 34.50, 15.70. HRMS (ESI-MS) m / z:[M+H] + calcd for C 26 H 25 ClN6O5S: 569.1374, found: 569.1379.
[0154] Example 16
[0155] N-(2-((4-benzoylphenyl)amino)-5-chloropyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide (PXW-16) has the following structure:
[0156]
[0157] Its synthetic route is as follows:
[0158]
[0159] The specific synthesis steps include:
[0160] Preparation of S1, N-(2,5-dichloropyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide: Same as step S1 in Example 13.
[0161] Preparation of S2 and N-(2-((4-benzoylphenyl)amino)-5-chloropyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide (PXW-16): Take a 50 mL reaction flask, add intermediate N-(2,5-dichloropyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide (500 mg) and 4-aminobenzophenone (303 mg) sequentially, add concentrated hydrochloric acid (0.6 mL), and then add isopropanol (12 mL) as the reaction solvent; after nitrogen purging protection, heat to 80℃ and maintain the reaction temperature for 8 h. Thin-layer chromatography (TLC) (developing solvent: V...) DCM :V MeOH = 9:1) Track the reaction endpoint. Cool the reaction solution to room temperature, slowly add triethylamine to adjust the pH of the system to 7-8, then concentrate under reduced pressure to remove the solvent to obtain the crude product; the crude product is purified by silica gel column chromatography (eluent: V PE V EA = 3:1), and after purification, the target compound PXW-16 was obtained, with a yield of 23% for this step. 1 H NMR (400 MHz, DMSO-d6) δ 10.61 (s,1H), 9.73 (s, 1H), 9.24 (s, 1H), 8.30 (s, 1H), 7.96 (d, J = 8.6 Hz, 2H),7.74-7.67 (m, 4H), 7.66-7.58 (m, 3H), 7.54-7.47 (m, 2H), 7.41 (d, J = 8.6 Hz,2H), 6.35 (t, J = 5.6 Hz, 1H), 3.18 - 3.10 (m, 2H), 1.06 (t, J = 7.2 Hz, 3H). 13C NMR (101MHz, DMSO-d6) δ 194.90, 154.97, 145.56, 144.52, 138.37, 133.03,132.53, 131.47, 131.39, 130.47, 129.91, 129.74, 129.42, 129.22, 127.19,118.93, 118.66, 117.23, 116.86, 113.06, 34.45, 15.79, 15.71. HRMS (ESI-MS) m / z: [M+H] + calcd for C 26 H 23 ClN6O4S: 551.1268, found: 551.1267.
[0162] Example 17
[0163] N-(2-((1H-indol-5-yl)amino)-5-chloropyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide (PXW-17) has the following structure:
[0164]
[0165] Its synthetic route is as follows:
[0166]
[0167] The specific synthesis steps include:
[0168] Preparation of S1, N-(2,5-dichloropyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide: Same as step S1 in Example 13.
[0169] Preparation of S2, N-(2-((1H-indole-5-yl)amino)-5-chloropyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide (PXW-17): Take a 50 mL reaction flask, and add intermediates N-(2,5-dichloropyrimidin-4-yl)-4-(3-ethylureo)benzenesulfonamide (500 mg), 1H-indole-5-amine (203 mg), p-toluenesulfonic acid monohydrate (244 mg), and isopropanol (12 mL) as the reaction solvent. After nitrogen purging protection, heat to 80℃ and maintain the reaction temperature for 72 h. Thin-layer chromatography (TLC) (developing solvent: V) DCM :V MeOH =9:1) Track the reaction endpoint. Cool the reaction solution to room temperature, slowly add triethylamine to adjust the pH of the system to 7-8, then concentrate under reduced pressure to remove the solvent to obtain the crude product; the crude product is purified by silica gel column chromatography (eluent: VPE :V EA The ratio of the two compounds was 1:3. After purification, the target compound PXW-17 was obtained, with a yield of 18% for this step. 1 H NMR (400 MHz, DMSO-d6) δ10.83 (s, 1H), 8.81 (s, 1H), 8.38 (s, 1H), 8.06 (s, 1H), 7.52 – 7.49 (m, 4H),7.23 (s, 1H), 7.13 (d, J = 7.8 Hz, 4H), 6.32 (d, J = 2.3 Hz, 1H), 3.03 (s,2H), 1.00 (t, J = 7.1 Hz, 3H). 13 C NMR (101MHz, DMSO-d6) δ 155.38, 145.91,142.69, 138.27, 132.22, 128.57, 128.08, 125.99, 125.56, 116.18, 115.87,111.06, 110.53, 101.28, 34.32, 15.81. HRMS (ESI-MS) m / z:[M+H] + calcd forC 21 H 20 ClN7O3S: 486.1115, found: 486.1119.
[0170] Example 18
[0171] N-(5-chloro-2-((4-phenoxyphenyl)amino)pyrimidin-4-yl)-4-(3-isopropylureo)benzenesulfonamide (PXW-18) has the following structure:
[0172]
[0173] Its synthetic route is as follows:
[0174]
[0175] The specific synthesis steps include:
[0176] Preparation of S1, N-(2,5-dichloropyrimidin-4-yl)-4-(3-isopropylureo)benzenesulfonamide: 2,4,5-trichloropyrimidin (1.00 g) and 4-(3-isopropylureo)benzenesulfonamide (1.19 g), along with anhydrous cesium carbonate (2.66 g), were added to a 100 mL pressure-resistant reaction flask and dissolved in acetonitrile (20 mL). The system was purged with nitrogen to create an inert protective atmosphere, and the mixture was heated to 80 °C and stirred for 12 h. Thin-layer chromatography (TLC) was used to analyze the reaction mixture (developing solvent: V...). DCM :V MeOH =7:1) Monitor the reaction progress. After the reaction is complete, allow the system to cool naturally to room temperature, concentrate under reduced pressure to remove the solvent, and purify the crude product by silica gel column chromatography (eluent: V). PE :V EA =1:5), yielding a pale yellow solid powder, N-(2,5-dichloropyrimidin-4-yl)-4-(3-isopropylurea)benzenesulfonamide (0.96 g, yield 45%). Characterization data: 1 H NMR (400 MHz, DMSO-d6) δ 10.68 (s, 1H), 9.55 (s, 1H), 9.18(s, 1H), 8.18 (s, 1H), 7.79 (d, J = 8.6 Hz, 2H), 7.67 - 7.61 (m, 2H), 7.44 -7.36 (m, 4H), 7.14 - 7.06 (m, 3H), 7.00 - 6.94 (m, 4H), 6.42 (d, J = 7.6 Hz,1H), 3.90 - 3.82 (m, 1H), 1.09 (d, J = 6.6 Hz, 6H). 13 C NMR (101 MHz, DMSO-d6)δ 165.40, 158.50, 155.80, 151.40, 145.20, 134.80, 132.60, 130.20, 129.40,123.20, 122.10, 120.00, 118.00, 117.00, 116.80, 46.20, 23.30. HRMS (ESI-MS)m / z: [M+H] + calcd for C 14 H 15 Cl2N5O3S: 403.0273, found: 403.0276.
[0177] Preparation of S2, N-(5-chloro-2-((4-phenoxyphenyl)amino)pyrimidin-4-yl)-4-(3-isopropylureo)benzenesulfonamide (PXW-18): Take a 50 mL reaction flask, add intermediates N-(2,5-dichloropyrimidin-4-yl)-4-(3-isopropylureo)benzenesulfonamide (500 mg) and 4-phenoxyaniline (276 mg) sequentially, add trifluoroacetic acid (209 μL), and then add isopropanol (12 mL) as the reaction solvent; after nitrogen purging protection, raise the temperature to 80℃ and maintain the reaction for 14 h. Thin-layer chromatography (TLC) (developing solvent: V...) DCM :V MeOH =8:1) Track the reaction endpoint. Cool the reaction solution to room temperature, slowly add triethylamine to adjust the pH of the system to 7-8, then concentrate under reduced pressure to remove the solvent and obtain the crude product; the crude product is purified by silica gel column chromatography (eluent: V PE :V EA The ratio of the two compounds was 1:2. After purification, the target compound PXW-18 was obtained, with a yield of 16% for this step. 1 H NMR (400 MHz, DMSO-d6) δ 10.95 (s,1H), 9.53 (s, 1H), 8.75 (s, 1H), 8.20 (s, 1H), 7.81 (d, J = 7.1 Hz, 2H),7.68-7.64 (m, 2H), 7.51-7.34 (m, 5H), 7.09 (t, J = 7.4 Hz, 1H), 7.01 – 6.97 (m, 4H), 6.16 (d, J = 7.5 Hz, 1H), 3.78 – 3.71 (m, 1H), 1.08 (d, J = 6.5 Hz,6H). 13 C NMR (101MHz, DMSO-d6) δ 158.18, 154.40, 130.42, 129.46, 123.25,122.13, 119.90, 118.11, 116.69, 46.22, 23.27. HRMS (ESI-MS) m / z: [M+H] + calcdfor C 26 H 25 ClN6O4S: 553.1425, found: 553.1428.
[0178] Example 19
[0179] N-(5-chloro-2-((4-(4-methoxyphenoxy)phenyl)amino)pyrimidin-4-yl)-4-(3-isopropylureo)benzenesulfonamide (PXW-19) has the following structure:
[0180]
[0181] Its synthetic route is as follows:
[0182]
[0183] The specific synthesis steps include:
[0184] Preparation of S1, N-(2,5-dichloropyrimidin-4-yl)-4-(3-isopropylurea)benzenesulfonamide: Same as S1 in Example 18.
[0185] Preparation of S2, N-(5-chloro-2-((4-(4-methoxyphenoxy)phenyl)amino)pyrimidin-4-yl)-4-(3-isopropylureo)benzenesulfonamide (PXW-19): Take a 50 mL reaction flask, and add intermediates N-(2,5-dichloropyrimidin-4-yl)-4-(3-isopropylureo)benzenesulfonamide (500 mg) and 4-(4-methoxyphenoxy)aniline (321 mg) sequentially. Add trifluoroacetic acid (208 μL), and then add isopropanol (12 mL) as the reaction solvent. After nitrogen purging protection, heat to 80℃ and maintain the reaction temperature for 5 h. Thin-layer chromatography (TLC) (developing solvent: V...) DCM :V MeOH =8:1) Track the reaction endpoint. Cool the reaction solution to room temperature, slowly add triethylamine to adjust the pH of the system to 7-8, then concentrate under reduced pressure to remove the solvent and obtain the crude product; the crude product is purified by silica gel column chromatography (eluent: V PE :V EA (The ratio of the two compounds was 1:3), and after purification, the target compound PXW-19 was obtained, with a yield of 33% for this step. 1 H NMR (400 MHz, DMSO-d6) δ 11.31 (s, 1H), 9.51 (s, 1H), 9.03 (s, 1H), 8.12 (s, 1H), 7.74 (d,J = 8.4 Hz, 2H), 7.67-7.61 (m, 2H), 7.39 (d, J = 8.6 Hz, 2H), 6.97 (d, 4H),6.93-6.88 (m, 2H), 6.50 (d, J = 7.5 Hz, 1H), 4.03 (q, J = 7.1 Hz, 1H), 3.74(s, 3H), 1.08 (d, J = 6.6 Hz, 6H). 13C NMR (101MHz, DMSO-d6) δ 159.03, 129.13,122.07, 120.16, 119.13, 118.56, 116.56, 115.50, 55.84, 46.14, 23.25. HRMS(ESI-MS) m / z: [M+H] + calcd for C 27 H 27 ClN6O5S: 583.1530, found: 583.1532.
[0186] I. Detection of HPK1 enzyme inhibitory activity:
[0187] Adopting ADP-Glo TM The inhibitory activity of the compounds against HPK1 enzyme was determined using a kinase assay system. In 384-well white microplates, 1 μL of a gradient concentration of the test compound working solution (starting at 10 μM, 3-fold dilution, 8 concentration gradients) or a solvent control was added, followed by 2 μL of HPK1 enzyme diluted with 1× Kinase Assay Buffer (containing 50 μM DTT) (final volume 1 ng / well). The blank control wells were treated with buffer instead of enzyme. 2 μL of MBP protein / ATP mixture was added to initiate the reaction (final concentration: 10 μM ATP, 0.1 mg / mL MBP protein), and incubated at 25°C for 2 hours. Then, 5 μL of ADP-Glo was added sequentially. TM The reagents (incubated at 25°C for 40 minutes) and 10 μL of Kinase Detection solution (incubated at 25°C for 30 minutes) were used to detect the chemiluminescence signal using a plate reader. The inhibition rate at each concentration was calculated using the following formula: Inhibition rate (%) = 100% - (RLU sample - RLU blank) / (RLU control - RLU blank) × 100%. The IC50 was calculated using a nonlinear regression fitting of the logarithm of compound concentration versus inhibition rate in GraphPad Prism software. 50 Values. The experimental results are shown in Table 1 below.
[0188] Table 1. Inhibitory activity of some compounds of the present invention against HPK1 enzyme
[0189] Compound serial number <![CDATA[HPK1 IC 50 (nM)]]> PXW-1 72.17 PXW-2 108.01 PXW-3 359.5 PXW-4 358.23 PXW-5 10.35 PXW-6 675.87 PXW-7 18.71 PXW-8 81.27 PXW-9 14.06 PXW-10 106.87 PXW-11 35.59 PXW-12 90.82 PXW-13 167.17 PXW-14 226.87 PXW-15 163.95 PXW-16 98.52 PXW-17 1425.54 PXW-18 331.24 PXW-19 261.95 AZ3246 8.33
[0190] Note: AZ3246 is a positive control compound.
[0191] II. CCK8 cell proliferation inhibition experiment:
[0192] A549 cells were cultured in Ham's F-12K complete medium (containing 10% fetal bovine serum and 1% penicillin-streptomycin) at 37°C and 5% CO2. Cells in the logarithmic growth phase were harvested and cultured at a concentration of 5 × 10⁻⁶ cells / cells. 3 Cells were seeded per well in 96-well plates and allowed to adhere overnight. Then, culture medium containing different concentrations of the test compounds (all compounds were dissolved in DMSO) was added, with a solvent control group included. The plates were incubated at 37°C in a 5% CO2 incubator for 48 hours. After incubation, 10 μL of enhanced CCK-8 reagent was added to each well, and the plates were incubated at 37°C for 2 hours. The absorbance (OD value) at 450 nm was measured using a microplate reader. The cell proliferation inhibition rate was calculated using the following formula: Inhibition rate (%) = [1 - (OD-treated group - OD-blank group) / (OD control group - OD-blank group)] × 100%. All experiments were performed in replicates, and the average proliferation inhibition rate was calculated. The experimental results are shown in Table 2 below.
[0193] Table 2. Inhibition rate of the compounds of this invention on the proliferation of A549 cells
[0194] Compound serial number 2μM cell proliferation inhibition rate 20μM cell proliferation inhibition rate PXW-1 19.55% 46.21% PXW-2 17.27% 42.96% PXW-3 10.47% 35.36% PXW-4 10.49% 31.38% PXW-5 31.52% 71.94% PXW-6 8.23% 20.19% PXW-7 28.69% 63.35% PXW-8 21.29% 54.71% PXW-9 24.13% 66.61% PXW-10 17.33% 47.58% PXW-11 26.46% 60.51% PXW-12 18.25% 38.35% PXW-13 14.80% 48.48% PXW-14 14.81% 34.81% PXW-15 14.91% 45.01% PXW-16 17.79% 43.89% PXW-17 2.68% 31.55% PXW-18 10.95% 31.41% PXW-19 12.26% 34.32% AZ3246 28.61% 40.78%
[0195] Note: AZ3246 is a positive control compound.
[0196] Jurkat cells were cultured in RPMI-1640 complete medium (containing 10% fetal bovine serum and 1% penicillin-streptomycin) at 37°C and 5% CO2. Logarithmic growth phase cells were harvested and cultured at 1×10⁻⁶ cells / cells. 4 Cells were seeded per well in a 96-well plate, and culture medium containing 20 μM of the test compound (all compounds were dissolved in DMSO) was added. A solvent control group was also included. The plates were incubated at 37°C with 5% CO2 for 48 hours. After incubation, 10 μL of enhanced CCK-8 reagent was added to each well, and the plates were incubated at 37°C for 3 hours. The absorbance (OD value) at 450 nm was measured using a microplate reader. The cell proliferation inhibition rate was calculated using the following formula: Inhibition rate (%) = [1 - (OD-treated group - OD-blank group) / (OD control group - OD-blank group)] × 100%. All experiments were performed in replicates, and the average proliferation inhibition rate was calculated. The experimental results are shown in Table 3 below.
[0197] Table 3. Inhibition rate of the compounds of this invention on Jurkat cell proliferation
[0198] Compound serial number 20μM cell proliferation inhibition rate PXW-1 38.42% PXW-2 42.15% PXW-3 31.38% PXW-4 39.76% PXW-5 86.29% PXW-6 32.57% PXW-7 79.84% PXW-8 69.52% PXW-9 75.61% PXW-10 48.37% PXW-11 73.48% PXW-12 35.26% PXW-13 51.84% PXW-14 49.63% PXW-15 52.71% PXW-16 47.92% PXW-17 28.65% PXW-18 32.19% PXW-19 45.83% AZ3246 71.35%
[0199] Raji cells were cultured in RPMI-1640 complete medium (containing 10% fetal bovine serum and 1% penicillin-streptomycin) at 37°C and 5% CO2. Cells in the logarithmic growth phase were harvested and cultured at a concentration of 1 × 10⁻⁶ cells / cells. 4Cells were seeded per well in a 96-well plate, and culture medium containing 20 μM of the test compound (all compounds were dissolved in DMSO) was added. A solvent control group was also included. The plates were incubated at 37°C in a 5% CO2 incubator for 48 hours. After incubation, 10 μL of enhanced CCK-8 reagent was added to each well, and the plates were incubated at 37°C for 3 hours. The absorbance (OD value) at 450 nm was measured using a microplate reader. The cell proliferation inhibition rate was calculated using the following formula: Inhibition rate (%) = [1 - (OD-treated group - OD-blank group) / (OD control group - OD-blank group)] × 100%. All experiments were performed in replicates, and the average proliferation inhibition rate was calculated. The experimental results are shown in Table 4 below.
[0200] Table 4. Inhibition rate of the compounds of this invention on Raji cell proliferation
[0201] Compound serial number 20μM cell proliferation inhibition rate PXW-1 28.27% PXW-2 35.84% PXW-3 26.95% PXW-4 35.42% PXW-5 71.46% PXW-6 27.73% PXW-7 74.21% PXW-8 66.38% PXW-9 71.75% PXW-10 37.64% PXW-11 71.93% PXW-12 39.82% PXW-13 46.51% PXW-14 44.76% PXW-15 47.28% PXW-16 45.37% PXW-17 25.24% PXW-18 28.62% PXW-19 41.59% AZ3246 65.47%
[0202] THP-1 cells were cultured in RPMI-1640 complete medium (containing 10% fetal bovine serum, 1% penicillin-streptomycin, and 0.05 mM β-mercaptoethanol) at 37°C and 5% CO2. Cells in the logarithmic growth phase were harvested and cultured at a concentration of 1 × 10⁻⁶ cells / cells. 4 Cells were seeded per well in a 96-well plate, and culture medium containing 20 μM of the test compound (all compounds were dissolved in DMSO) was added. A solvent control group was also included. The plates were incubated at 37°C with 5% CO2 for 48 hours. After incubation, 10 μL of enhanced CCK-8 reagent was added to each well, and the plates were incubated at 37°C for 3 hours. The absorbance (OD value) at 450 nm was measured using a microplate reader. The cell proliferation inhibition rate was calculated using the following formula: Inhibition rate (%) = [1 - (OD-treated group - OD-blank group) / (OD control group - OD-blank group)] × 100%. All experiments were performed in replicates, and the average proliferation inhibition rate was calculated. The experimental results are shown in Table 5 below.
[0203] Table 5. Inhibition rate of the compounds of this invention on the proliferation of THP-1 cells
[0204] Compound serial number 20μM cell proliferation inhibition rate PXW-1 26.83% PXW-2 33.72% PXW-3 25.47% PXW-4 34.08% PXW-5 69.54% PXW-6 27.91% PXW-7 72.38% PXW-8 59.26% PXW-9 66.42% PXW-10 29.15% PXW-11 64.74% PXW-12 38.36% PXW-13 35.18% PXW-14 33.59% PXW-15 45.07% PXW-16 39.62% PXW-17 18.83% PXW-18 27.15% PXW-19 39.24% AZ3246 65.28%
[0205] As shown in Tables 1-5, the compounds of the present invention exhibit varying degrees of inhibitory activity against the proliferation of various tumor cells (including A549, Jurkat, Raji, and THP-1). Some compounds (such as PXW-5 and PXW-9) show strong inhibitory effects on proliferation at a concentration of 20 μM and have nanomolar inhibitory activity against HPK1 enzyme, demonstrating good potential for HPK1 kinase inhibition.
[0206] Although the technical solutions of the present invention have been disclosed above, they are not limited to the applications listed in the specification and embodiments. They can be applied to various fields suitable for the present invention. For those skilled in the art, other modifications can be easily made. Therefore, without departing from the general concept defined by the claims and their equivalents, the present invention is not limited to the specific details and embodiments shown and described herein.
Claims
1. A 2-aminopyrimidine compound having the structure shown in general formula (I) or a pharmaceutically acceptable salt thereof, (I); in, R1 is independently selected from oxygen-bridged biaromatic ring structural units, carbonyl-bridged biaromatic ring structural units, or benzo[a]heterocyclic rings; the oxygen-bridged biaromatic ring structural unit is... , or The carbonyl-bridged biaromatic ring structural unit is In this configuration, R4 is selected from hydrogen, methyl, or methoxy; R2 is selected solely from halogens; and R3 is a 4-position substituent on the benzene ring of the benzenesulfonamide, wherein R3 is selected solely from C1-C6 alkyl, C1-C6 alkoxy, or... Wherein, R5 is a C1 to C3 alkyl group, or In this case, R6 is a C1 to C3 alkyl group.
2. The 2-aminopyrimidine compound or a pharmaceutically acceptable salt thereof as described in claim 1, characterized in that, R2 is Cl.
3. The 2-aminopyrimidine compound or a pharmaceutically acceptable salt thereof as described in claim 1, characterized in that, R3 is selected from methyl, methoxy, tert-butyl, ... , or .
4. The 2-aminopyrimidine compound or a pharmaceutically acceptable salt thereof as described in claim 1, characterized in that, 2-aminopyrimidine compounds having the structure shown in general formula (I) are one of the following compounds from formula 1 to formula 19: Formula 1 Formula 2 Formula 3 Formula 4 Formula 5 Formula 6 Formula 7 Formula 8 Formula 9 Formula 10 Formula 11 Formula 12 Formula 13 Formula 14 Formula 15 Formula 16 Formula 17 Formula 18 Formula 19.
5. A method for preparing the 2-aminopyrimidine compound according to any one of claims 1 to 4, characterized in that, Includes the following steps: S1. Using 2,4,5-trichloropyrimidine as a starting material, it reacts with R3-substituted benzenesulfonamide under the presence of a base and under nitrogen protection by heating. After the reaction, it is purified to obtain an intermediate with the structure of formula (II) as follows. S2, intermediate and R1NH2 reacted with a protic acid catalyst under heating. After the reaction, the reaction solution was cooled, the pH was adjusted to 7-8, concentrated and purified by column chromatography to obtain 2-aminopyrimidine compounds of general formula (I). (II).
6. The method for preparing 2-aminopyrimidine compounds as described in claim 5, characterized in that, In step S1, the molar ratio of 2,4,5-trichloropyrimidine to R3-substituted benzenesulfonamide is (1-2):1, the base is N,N-diisopropylethylamine, anhydrous potassium carbonate or anhydrous cesium carbonate; the temperature for heating the reaction is 70-100℃, and the reaction time is 3-12 h.
7. The method for preparing 2-aminopyrimidine compounds according to claim 5, characterized in that, In step S2, the molar ratio of the intermediate to R1NH2 is 1:(1-2), and the protic acid catalyst is trifluoroacetic acid, concentrated hydrochloric acid, or p-toluenesulfonic acid monohydrate.
8. The method for preparing 2-aminopyrimidine compounds as described in claim 5, characterized in that, In step S2, the heating temperature is 60-80℃, the reaction time is 3-72 h, and the eluent used for column chromatography purification is petroleum ether and ethyl acetate in a volume ratio of (1-9):(1-3).
9. The use of the 2-aminopyrimidine compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 4 in the preparation of a medicament for treating non-small cell lung cancer, acute T-lymphoblastic leukemia, B-cell lymphoma or acute monocytic leukemia.
